Detalhe da pesquisa
1.
T-cell dysfunctions in myelodysplastic syndromes.
Blood
; 143(14): 1329-1343, 2024 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237139
2.
Telomere dysfunction instigates inflammation in inflammatory bowel disease.
Proc Natl Acad Sci U S A
; 118(29)2021 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34253611
3.
A machine learning-based method for automatically identifying novel cells in annotating single-cell RNA-seq data.
Bioinformatics
; 38(21): 4885-4892, 2022 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36083008
4.
Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.
Haematologica
; 108(10): 2626-2638, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37078252
5.
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
Nature
; 542(7641): 362-366, 2017 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28178232
6.
A road map of relapse in MDS after allo-HSCT.
Blood
; 143(11): 941-943, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38483410
7.
Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function.
Nature
; 514(7524): 628-32, 2014 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25119024
8.
PAF promotes stemness and radioresistance of glioma stem cells.
Proc Natl Acad Sci U S A
; 114(43): E9086-E9095, 2017 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29073105
9.
Dysfunctional telomeres and hematological disorders.
Differentiation
; 100: 1-11, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29331736
10.
Passenger deletions generate therapeutic vulnerabilities in cancer.
Nature
; 488(7411): 337-42, 2012 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-22895339
11.
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
Lancet Oncol
; 18(1): 100-111, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27923552
12.
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Am J Hematol
; 92(4): 351-358, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28076892
13.
Telomere dysfunction induces metabolic and mitochondrial compromise.
Nature
; 470(7334): 359-65, 2011 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-21307849
14.
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells.
Nature
; 468(7324): 701-4, 2010 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-21124456
15.
Corrigendum: Passenger deletions generate therapeutic vulnerabilities in cancer.
Nature
; 525(7568): 278, 2015 Sep 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26153864
16.
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes.
Nat Commun
; 15(1): 2428, 2024 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38499526
17.
Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia.
Cell Rep Med
; : 101585, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38781960
18.
STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response.
Leukemia
; 38(5): 1143-1155, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38467768
19.
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study.
Lancet Haematol
; 11(3): e186-e195, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38316133
20.
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML.
Nat Commun
; 15(1): 4739, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38834613